• Explore /
  • Poster
  • / Synergistic activity of PARP inhibitors (PARPi) in combination with standard chemotherapy (CTx) in leiomyosarcoma.

Synergistic activity of PARP inhibitors (PARPi) in combination with standard chemotherapy (CTx) in leiomyosarcoma.

Abstract Poster

Authors

Olga Vornicova

Olga Vornicova

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Olga Vornicova , Yael Babichev , Rima Al-awar , Richard Marcellus , Albiruni Ryan Abdul Razak , Rebecca Anne Gladdy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 11560)

DOI

10.1200/JCO.2022.40.16_suppl.11560

Abstract #

11560

Poster Bd #

464

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

First Author: Matthew Ingham

First Author: Kristine Peregrino Lacuna

First Author: Syed Arsalan Ahmed Naqvi

First Author: Robert Hettle